Literature DB >> 15875925

Severe hepatotoxicity due to anti-tuberculosis drugs in Spain.

J R Tost1, R Vidal, J Caylà, D Díaz-Cabanela, A Jiménez, J M Broquetas.   

Abstract

OBJECTIVES: To determine the frequency of severe hepatotoxicity due to anti-tuberculosis (TB) drugs, and predictors of development of acute liver failure or of death.
METHODS: A retrospective study conducted by members of the Spanish Society of Pneumology from 18 hospitals during 1997-2001. A case of severe hepatotoxicity was defined as any asymptomatic patient with a ten-fold increase in transaminases or three-fold increase in colostasis parameters, or, among patients with hepatitis symptoms, any raised hepatic parameters or development of hepatic failure. Predictive factors were studied using logistic regression, calculating odds ratios (OR) and their 95% confidence intervals (CI).
RESULTS: One hundred and six patients developed severe hepatotoxicity. Of a total of 3510 patients, 90 were treated for active TB (2.56%). Eleven cases (10.3%) presented with acute liver failure, three of whom underwent liver transplant. The global case fatality rate was 4.7% (five cases, three associated with alcohol use or hepatotoxic drugs). The predictors of poor prognosis were total bilirubin > 2 mg/dl (OR 9.4, 95% CI 1.0-85.5) and serum creatinine > 1.5 mg/dl (OR 32.1, 95% CI 2.4-424.6).
CONCLUSIONS: Severe hepatotoxicity due to anti-tuberculosis drugs is associated with a high fatality rate. Prevention should be based on informing patients and frequent clinical and laboratory controls.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875925

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  15 in total

1.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.

Authors:  Serena P Koenig; Bruce R Schackman; Cynthia Riviere; Paul Leger; Macarthur Charles; Patrice Severe; Charlene Lastimoso; Nicole Colucci; Jean W Pape; Daniel W Fitzgerald
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

3.  Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.

Authors:  Xin Shen; Zheng'an Yuan; Jian Mei; Zurong Zhang; Juntao Guo; Zheyuan Wu; Jie Wu; Haihua Zhang; Jieping Pan; Wenming Huang; Huili Gong; Dong Yuan; Ping Xiao; Yanqin Wang; Yi Shuai; Senlin Lin; Qichao Pan; Tong Zhou; Paul B Watkins; Fan Wu
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

Review 4.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

Review 5.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

6.  Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.

Authors:  Yuag-Meng Liu; Yu-Jen Cheng; Yu-Lin Li; Chun-Eng Liu; Wu-Huei Hsu
Journal:  Lung       Date:  2013-11-30       Impact factor: 2.584

7.  Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis.

Authors:  Zaher Al-Salmi
Journal:  Saudi Pharm J       Date:  2011-09-23       Impact factor: 4.330

8.  Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients.

Authors:  Mark H Kuniholm; Jennifer Mark; Malvina Aladashvili; N Shubladze; G Khechinashvili; Tengiz Tsertsvadze; Carlos del Rio; Kenrad E Nelson
Journal:  Int J Infect Dis       Date:  2007-07-23       Impact factor: 3.623

Review 9.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

10.  Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study.

Authors:  Natalie Lorent; Osee Sebatunzi; Gloria Mukeshimana; Jef Van den Ende; Joannes Clerinx
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.